Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14843303 | 0.99 | BUB1 (0.98) | BUB1 | |
| SCHEMBL16129328 | 0.92 | BUB1 (0.86) | BUB1 | |
| SCHEMBL14843675 | 0.92 | BUB1 (1.00) | BUB1 | |
| SCHEMBL14844920 | 0.91 | BUB1 (0.85) | BUB1 | |
| SCHEMBL14843804 | 0.91 | BUB1 (1.00) | BUB1 | |
| SCHEMBL19352651 | 0.91 | BUB1 (0.85) | BUB1 | |
| SCHEMBL14843277 | 0.91 | BUB1 (0.88) | BUB1 | |
| SCHEMBL14843487 | 0.90 | BUB1 (1.00) | BUB1 | |
| SCHEMBL15991417 | 0.90 | BUB1 (0.82) | BUB1 | |
| SCHEMBL14845254 | 0.90 | BUB1 (0.85) | BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-19 | — | — | US | claimed |
| EP-2763982-B1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | Bayer Pharma AG (DE) | 2018-01-10 | — | — | EP | claimed |
| US-20170260198-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-09-14 | — | — | US | claimed |
| US-9265763-B2 | — | — | 2016-02-23 | — | — | US | claimed |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | claimed |
| US-10604532-B2 | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-10604532-B2 | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| EP-2763982-B1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | Bayer Pharma AG (DE) | 2018-01-10 | — | — | EP | disclosed |
| US-9265763-B2 | — | — | 2016-02-23 | — | — | US | disclosed |
| US-9265763-B2 | — | — | 2016-02-23 | — | — | US | disclosed |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | US | disclosed |
| EP-2763982-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | Bayer Pharma Aktiengesellschaft (DE) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013050438-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050438-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604532-B2 | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | BUB1, BUB1B, BUB3 | BUB1 1/4885 |
| US-20140249133-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | BUB1 1/4885 |
| US-20170260198-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | BUB1 1/4885 |
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | BUB1 1/4885 |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BUB1, BUB1B, BUB3 | BUB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.